Business Wire

Dine Brands Expands Global Footprint With New Deals and First Dual-Branded Applebee’s® and IHOP® Location in Honduras

9.9.2024 15:00:00 CEST | Business Wire | Press release

Share

Parent company of the world’s favorite restaurant brands extends dual-branded strategy to new international market.

Dine Brands International, an affiliate of Dine Brands Global, Inc., the parent company of Applebee’s®, IHOP®, and Fuzzy’sTaco Shop® restaurants, is further expanding its global footprint and unique dual-branded Applebee’s and IHOP concept to new international markets. Through a multi-unit development agreement with franchisee BLT Global Brands, the first dual-branded restaurant in San Pedro Sula, Honduras is planned to open on September 16, 2024.

Dine Brands' entry into Honduras marks a significant milestone in the company's international expansion strategy. This new location showcases the innovative dual-branded restaurant concept, which presents guests with two distinct IHOP and Applebee’s branded dining areas to choose from, while providing efficiencies in prototype design and operating model for franchisees. The unique dining experience allows guests to enjoy the best of both beloved brands, from IHOP's world-famous breakfast offerings to Applebee's diverse menu of casual dining favorites.

“We’re excited to bring IHOP and Applebee’s to Honduras. The country’s vibrant culture and growing economy make it an ideal location for this dual-branded concept, offering a unique blend of comfort and quality in a lively and inviting dining atmosphere,” said Thomas Christopher Talarico, CEO of BLT Global Brands.

“I am incredibly proud of the progress we are making to connect with and to expand to new guests around the world with the support of our franchisees,” added Scott Gladstone, Chief Development Officer, and President, International at Dine Brands Global. “By leveraging IHOP’s morning popularity and Applebee’s evening appeal, we can cover all day parts and bring delicious and memorable dining experiences with world-class service to guests every day. So far, we have been pleased with the improved overall performance and returns of our dual-branded restaurants.”

With this opening, the total number of international dual-branded restaurants will reach 13 locations across 7 markets: Mexico, Canada, UAE, Kuwait, Saudi Arabia, Peru and Honduras. Leveraging this innovative concept, Dine Brands International has recently secured agreements to develop at least 21 new locations, 13 of which will be dual-branded, in various international markets. These commitments represent both conversions of existing single-branded restaurants as well as new restaurants in both traditional and non-traditional channels, including airports and travel centers.

Dine Brands is seeking qualified Master Franchisees and Developers across select markets in Asia, including South Korea and Japan; select markets in Europe, including Spain; Brazil; and select territories in Mexico and Canada. For franchising opportunities, please visit https://franchise.ihop.com/en/applebees-co-branded-franchising.

About Dine Brands Global, Inc.

Based in Pasadena, California, Dine Brands Global, Inc. (NYSE: DIN), through its subsidiaries and franchisees, supports and operates restaurants under the Applebee’s Neighborhood Grill + Bar®, IHOP®, and Fuzzy’s Taco Shop® brands. As of June 30, 2024, these three brands consisted of close to 3,600 restaurants across 18 international markets. Dine Brands is one of the largest full-service restaurant companies in the world and in 2022 expanded into the Fast Casual segment. For more information on Dine Brands, visit the company’s website located at www.dinebrands.com.

BR-INTL

View source version on businesswire.com: https://www.businesswire.com/news/home/20240909342681/en/

Contacts

Media Contact

Media Contact
Heather Mann
Director, Global Communications
Dine Brands Global, Inc.
Heather.mann@dinebrands.com

Heather.mann@dinebrands.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye